Lilly To Bring Forward Alzheimer’s Readout
Gamble By Rivals Biogen Is Likely Inspiration
Executive Summary
After years of failure, expectations of solanezumab are very low – but Lilly still hoping for a signal.
You may also be interested in...
Another Alzheimer's Setback As Roche And Lilly Drugs Fail
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.